Cargando…

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients

Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohuchi, Kentaro, Kambayashi, Yumi, Hidaka, Takanori, Fujimura, Taku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666429/ https://www.ncbi.nlm.nih.gov/pubmed/34912726 http://dx.doi.org/10.3389/fonc.2021.798385

Ejemplares similares

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
por: Fujimura, Taku, et al.
Publicado: (2020)

LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages
por: Ohuchi, Kentaro, et al.
Publicado: (2023)

Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer
por: Fujimura, Taku, et al.
Publicado: (2018)

Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
por: MUTO, Yusuke, et al.
Publicado: (2022)

Treatment of Advanced Melanoma: Past, Present and Future
por: Fujimura, Taku, et al.
Publicado: (2020)

Serum CCL22 Increased in Advanced Melanoma Patients with Liver Metastases: Report of 5 Cases
por: Ohuchi, Kentaro, et al.
Publicado: (2022)

Pigmented Epithelioid Melanocytoma (Animal Types of Melanoma) on the Nose
por: Ohuchi, Kentaro, et al.
Publicado: (2018)

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock
por: Muto, Yusuke, et al.
Publicado: (2020)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
por: Furudate, Sadanori, et al.
Publicado: (2016)

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2022)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
por: Fujimura, Taku, et al.
Publicado: (2019)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)

Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
por: Fujimura, Taku, et al.
Publicado: (2012)

Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene
por: Chiba, Hiromu, et al.
Publicado: (2022)

Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab
por: Amagai, Ryo, et al.
Publicado: (2023)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
por: Fujimura, Taku, et al.
Publicado: (2017)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

First-in-human clinical study of novel technique to diagnose malignant melanoma via thermal conductivity measurements
por: Okabe, Takahiro, et al.
Publicado: (2019)

Recurrent Multiple Squamous Cell Carcinomas on the Scalp in a Patient with Juvenile Dermatomyositis
por: Sato, Yota, et al.
Publicado: (2017)

Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy
por: Tanita, Kayo, et al.
Publicado: (2017)

IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation
por: Yoshida, Saaya, et al.
Publicado: (2020)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
por: Liu, Ye, et al.
Publicado: (2021)

Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages
por: Kakizaki, Aya, et al.
Publicado: (2015)

Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis
por: Wu, Shuang, et al.
Publicado: (2021)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab
por: Tanita, Kayo, et al.
Publicado: (2018)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab
por: Furudate, Sadanori, et al.
Publicado: (2017)

Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163(+) Arginase 1(+) M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma
por: Fujimura, Taku, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i0nul48pmgdv6olv2r8ne2em4f